Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment
| Autor: | Grazyna A. Stanczuk, Gwen Baxter, Heather Currie, Kate Cuschieri, Adele Foster, Lindsay Gibson, Catriona Graham |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
medicine.medical_specialty Concordance Population Uterine Cervical Neoplasms Urine Cervix Uteri Urinalysis Cervical intraepithelial neoplasia Pathology and Forensic Medicine Human Papillomavirus DNA Tests Specimen Handling Young Adult Predictive Value of Tests medicine Prevalence Humans education Cervix Papillomaviridae Colposcopy Gynecology Cervical cancer education.field_of_study Cervical screening medicine.diagnostic_test business.industry Papillomavirus Infections virus diseases High-Throughput Nucleotide Sequencing Reproducibility of Results General Medicine Middle Aged medicine.disease Uterine Cervical Dysplasia female genital diseases and pregnancy complications medicine.anatomical_structure Treatment Outcome Scotland DNA Viral Vagina Female Neoplasm Grading business |
| Zdroj: | Journal of clinical pathology. 68(7) |
| ISSN: | 1472-4146 |
| Popis: | Aims To assess the performance of a clinically validated human papillomavirus (HPV) test (the Cobas 4800 HPV test) in urine and self-taken vaginal specimens within a colposcopy population and to assess HPV prevalence before and after treatment across the different biospecimens. Methods A total of 100 women attending a colposcopy clinic provided three biospecimens (a clinician-taken liquid-based cytology sample (LBC), a self-taken vaginal sample and a urine sample) for HPV testing. HPV prevalence and concordance was compared across the biospecimens and clinical performance relative to the detection of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ was assessed. A total of 39 women retuned at 6 months for a post-treatment follow-up appointment, and HPV concordance in all biospecimens was measured relative to their original HPV status. Results 65 cases of CIN2+ were detected in the baseline population; sensitivity for CIN2+ was 92% (82 to 97) for the vaginal and the LBC sample and 80.0 (68% to 88%) for the urine sample. In the follow-up (post treatment) population, women were twice as likely to be HPV positive in their urine or vaginal sample compared with the equivalent LBC sample. Conclusions Vaginal and LBC samples showed very similar performance for the detection of CIN2+ in this population using the Cobas HPV test; further validation of these findings in screening contexts will be of value. Self-taken samples may have less utility in a ‘test of cure’ setting—given the higher prevalence of HPV relative to LBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|